Jubilant Pharmova Limited’s wholly-owned subsidiary, Jubilant HollisterStier LLC (JHS), a leading North American contract manufacturer of sterile injectables, has successfully launched its third Sterile Fill & Finish Line at its Spokane, Washington manufacturing facility. The inaugural batch has been produced, marking the commencement of revenue generation from the new line.
The US$132 million investment in the Third Line enhances operational throughput, sterility assurance, and precision with advanced isolator technology. This expansion represents a 50% increase in capacity at the Spokane site and is a critical milestone in JHS’ multi-phase growth strategy.
“Launching our Third Line is a defining moment for Jubilant HollisterStier,” said Chris Preti, CEO – CDMO Sterile Injectables. “With the Fourth Line under development, we are on track to double total sterile injectable manufacturing capacity in Spokane. This expansion strengthens the US pharmaceutical supply chain, creates hundreds of new jobs, and reinforces our role as a trusted partner for life-saving therapies.”
The Third Line is designed to meet the highest global regulatory standards, supporting complex injectable programs across multiple therapeutic areas. JHS’ infrastructure expansion aims to increase onshore manufacturing capacity for US pharma companies, reducing reliance on offshore supply chains and enhancing national health security.
JHS, trusted by five of the top 20 global pharmaceutical companies, has a 92% customer retention rate and a proven compliance record with regulatory authorities, including the US FDA, EMA, PMDA Japan, Health Canada, and ANVISA Brazil, covering over 140 countries worldwide.
“In light of recent US tariffs, demand for high-quality domestic manufacturing has surged,” Preti added. “We are already seeing strong traction in Requests for Proposals for the new line and expect full utilization within three years.”
The commissioning of the Third Line positions JHS as a leading partner for innovator pharma companies, combining capacity growth with technological excellence to meet global sterile injectable demands.